Doxycycline Composition with Segmented Release for pH-Independent Rosacea Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current doxycycline compositions for treating rosacea do not provide a continuous drug release independent of the gastrointestinal tract's pH, limiting their effectiveness.
Innovation Solution
A pharmaceutical composition comprising 50% to 99% doxycycline as an immediate-release portion and 1% to 50% doxycycline with a controlled-release polymer as a controlled-release portion, providing a total daily dosage of 40 mg when administered once daily, which ensures continuous drug release regardless of pH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If doxycycline is formulated with enteric coating for delayed-release, then the drug is protected from acidic stomach environment and released only in small intestine, but the release becomes pH-dependent and not continuous
Solution Approach 1:
The patent divides the doxycycline dosage into two separate portions: an immediate-release portion (50-95% of total dosage) that releases drug quickly in the stomach, and a controlled-release portion (5-50% of total dosage) that releases drug slowly over time. This segmentation allows the drug to be released continuously regardless of pH conditions, resolving the contradiction between reliable release and pH independence.
Solution Approach 2:
The patent changes the release kinetics parameter by combining immediate-release and controlled-release mechanisms. The controlled-release portion uses polymers or matrix systems to achieve sustained release over 12-24 hours, while the immediate-release portion provides rapid initial release. This parameter change enables continuous drug release independent of gastrointestinal pH variations.
2Duration of action of moving object
If doxycycline is administered in multiple doses throughout the day, then continuous drug levels can be maintained, but patient compliance and ease of operation deteriorate
Solution Approach 1:
The patent achieves continuous drug release through a single daily dose by combining immediate-release and controlled-release portions. The controlled-release portion is designed to release doxycycline slowly over 12-24 hours, maintaining therapeutic levels throughout the day without requiring multiple administrations. This provides continuous useful action while simplifying dosing to once daily.
Solution Approach 2:
The patent uses dynamic release kinetics where the controlled-release portion adjusts drug release rate to maintain steady plasma concentrations over time. The system transitions from rapid initial release to sustained slower release, dynamically adapting to maintain therapeutic levels throughout the dosing interval without requiring patient intervention.
3Quantity of substance
If sub-antimicrobial doses of doxycycline are used for rosacea treatment, then therapeutic efficacy is achieved, but the drug concentration may be insufficient without continuous release
Solution Approach 1:
The immediate-release portion provides preliminary action by rapidly releasing a significant portion of the doxycycline dose (50-95%) at the beginning, achieving quick therapeutic effect. The controlled-release portion then maintains sub-antimicrobial levels throughout the day, ensuring continuous therapeutic action without requiring high total doses.
Solution Approach 2:
The patent uses a composite formulation combining immediate-release doxycycline (50-95%) and controlled-release doxycycline (5-50%). This composite approach allows the same tablet to provide both rapid initial drug levels and sustained sub-antimicrobial concentrations, achieving effective rosacea treatment with a single daily dose of 40mg or less.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves a consistent and prolonged release of doxycycline, enhancing its therapeutic efficacy for rosacea treatment by maintaining a steady drug concentration.
Implementation Method 1
a controlled-release portion comprising 1% to 50% of doxycycline, a controlled-release polymer
Implementation Method 2
a controlled-release portion comprising 1% to 50% of doxycycline, a controlled-release polymer
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising (i) 50% to 99% of doxycycline as an immediate-release portion; (ii) 1% to 50% of doxycycline as a controlled-release portion; and (iii) one or more pharmaceutically acceptable excipients; wherein the pharmaceutical composition provides a total daily dosage of 40 mg when administered once daily. It also relates to process for preparation of the pharmaceutical composition and its use for treating rosacea.